Key takeaway: The investor presentation for Mankind Pharma Limited (MANKIND) for Q2 and H1 FY27 reports revenue growth of 17% YoY, with EBITDA up 27% and PAT up 38%. Domestic business grew 16% YoY, driven by strong performance in chronic and acute segments, including 19% growth in Cardiac and 26% in VMN. International business grew 33%, supported by new product launches in the US. The company highlighted disciplined execution and strategic acquisitions, such as Armed Cell Therapeutics, to strengthen R&D capabilities. Consumer healthcare revenue grew 1.2% YoY, with market share gains in key brands despite industry-wide slower offtake. Exports increased 32.7% YoY, with Mankind launching one new product in Q2FY27. The consolidated P&L showed improved gross margins and EBITDA margins, with PAT margins rising 240 bps YoY. The company emphasized its robust distribution network and R&D infrastructure, with 7 dedicated facilities and over 740 scientists. Management noted challenges including industry-specific risks and regulatory uncertainties, as outlined in the Safe Harbour statement.

Key takeaway: Mankind Pharma Limited reported a 13% year-on-year increase in overall revenue for Q1 FY27, reaching INR 4,031 crores, with an EBITDA of INR 1,060 crores and an EBITDA margin improvement of 250 bps to 26.3%. The domestic business, excluding Consumer Healthcare, grew by 11% to INR 3,180 crores, driven by strong performance in chronic and specialty segments. The company noted a significant shift towards chronic therapies, with a 40% share in chronic business, aiming for 50% in the medium term. The Consumer Healthcare segment generated INR 246 crores, impacted by a discontinued cash and carry business but gained market share in key brands. The international business saw a 29% revenue growth to INR 605 crores. Management emphasized a focus on innovation and strategic partnerships to enhance R&D capabilities. The company aims for sustainable long-term growth while maintaining affordability in healthcare.

Key takeaway: The investor presentation for Mankind Pharma Limited reported a revenue growth of approximately 13% year-over-year for Q1 FY27, with EBITDA margins improving by 250 basis points to 26.3%. The domestic business, excluding consumer healthcare, grew by 11%, driven by strong performances in chronic segments such as cardiac and anti-diabetes. The OTC segment saw a growth of around 4%, while international business revenue increased by 29%. Key financial metrics included a profit after tax of INR 574 crore, reflecting a 29.1% year-over-year growth. The presentation highlighted strong growth in specific brands and segments, with a consistent focus on expanding chronic contributions. Mankind maintained its market leadership in several therapeutic areas and reported a healthy growth trajectory across its business segments, supported by strategic initiatives and product launches.

Key takeaway: Mankind Pharma Limited held its Q4 FY26 earnings conference call on May 20, 2026, where management reported an 11.8% year-on-year revenue increase to INR 3,443 crores for the quarter, and a 17.0% increase to INR 14,278 crores for the full year. The adjusted EBITDA margin for Q4 was 27.1%, up from 23.1% in Q4 FY25. Domestic revenue, excluding Consumer Healthcare, grew by 12.9% in Q4, driven by strong performance in the specialty business. Management highlighted a 2.3% volume growth for FY26, an increase from 0.5% the previous year. The company acquired the brand Rivotril from Roche to enhance its specialty portfolio. The OTC business saw a 20% revenue increase in Q4, attributed to growth in modern trade and e-commerce. Management expressed confidence in regaining growth momentum and emphasized a strategic focus on specialty chronic therapies and R&D-led innovation.

Key takeaway: The investor presentation from Mankind Pharma Limited detailed the company's financial results for the quarter and financial year ended March 31, 2026. Management reported a revenue increase of approximately 12% year-over-year, with adjusted EBITDA margins at 27.1%. The domestic business, excluding consumer healthcare, grew by around 13%, driven by strong performances in cardiac and anti-diabetes segments. The OTC business saw a 20% growth, while international business growth was muted due to geopolitical challenges. The presentation highlighted a focus on expanding specialty and super specialty segments, with a strategy centered on steady base business growth and enhancing market share in chronic therapies. Key financial metrics included a net debt of INR 3,932 crore and a return on capital employed of 12%. The document also outlined the company's commitment to sustainable growth and ESG initiatives.

Key takeaway: During the earnings call for Q3 and 9M FY26, management reported an 11.5% year-on-year increase in overall revenue to INR3,567 crores, with an adjusted EBITDA margin of 25.9%. For the first nine months, revenue rose by 18.7% to INR10,835 crores. The domestic business grew by 11.1%, driven by strong performance in chronic therapies, particularly in cardio and antidiabetes segments. Management highlighted a gradual recovery in the acute segments and emphasized the importance of workforce stability and digital transformation initiatives. The OTC business showed signs of improvement, with a 5.2% year-on-year growth in Q3. Export revenues increased by 14% year-on-year. Management acknowledged challenges in the anti-infective segment but expressed confidence in future growth driven by strategic initiatives and a focus on brand performance. The call concluded with management inviting questions from analysts.

Key takeaway: The investor presentation for Mankind Pharma Limited for Q3 FY26 reported an 11.5% year-over-year increase in revenue, reaching INR 3,567 crore, with adjusted EBITDA margins of 25.9%. Management highlighted strong growth in the domestic pharma sector, particularly in chronic therapies, with a 200 basis points increase in chronic share to 39.3%. The presentation noted a 5.2% growth in OTC revenue compared to a decline in the previous quarter. BSV growth initiatives were described as progressing well, contributing to double-digit growth. Management emphasized a long-term growth strategy anchored by a steady base business, expanding specialty chronic segments, and a high-potential OTC business. The document also provided insights into financial metrics, including a net debt of INR 4,294 crore and a focus on maintaining strong cash flow and profitability. Overall, the presentation outlined a positive trajectory in financial performance and strategic initiatives.